Biological and clinical role of p73 in neuroblastoma
Massimo Romani(Ospedale Policlinico San Martino), Ida Casciano(Alleanza Contro il Cancro), Gabriella Pagnan(Istituto Giannina Gaslini), Silvano Ferrini(Ospedale Policlinico San Martino), Katia Mazzocco(Istituto Giannina Gaslini), Gian Paolo Tonini(Città della Speranza Foundation), Mirco Ponzoni(Istituto Giannina Gaslini), Barbara Banelli(Ospedale Policlinico San Martino), Giorgio Allemanni(Alleanza Contro il Cancro), Paola Scaruffi(Azienda Ospedaliera S.Maria), Michela Croce(Ospedale Policlinico San Martino), Luca Boni(Ospedale Policlinico San Martino), Lizzia Raffaghello(Istituto Giannina Gaslini)
Cited by 18
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Dysregulated metabolism contributes to oncogenesis
|Seminars in Cancer Biology|2015|318